Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Ember Therapeutics Acquires Dermasilk™ Brands


Posted on: 13 Sep 16

NEW YORK, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that it has entered into a definitive agreement for the acquisition of Dermasilk™ Brands, a commercially available over-the-counter beauty product portfolio encompassing fourteen different products. The products are currently sold at several large retailers including Rite-Aid, CVS, Wal-Mart and K-Mart.

As part of the transaction, all assets from Dermasilk Brands, Inc. will be transferred to Ember Therapeutics, Inc.

“This is our third acquisition this year. The addition of the Dermasilk™ brand of products to our product line will allow us to expand on our current relationship with major retailers and provide additional revenues to Ember. Dermasilk products have a large customer following and are developed using the highest cutting edge science,” said Joseph Hernandez, Executive Chairman of Ember Therapeutics, Inc. “The revenues generated by these products and Migralex™, our other commercially available product, will help further the development of our two Phase 3 ready clinical programs in osteoarthritis and regenerative medicine.”

Dermasilk™ products are currently available at Rite-Aid, CVS, Wal-Mart, K-Mart, local pharmacies, and online at jet.com and the product website www.dermasilkbrands.com. To learn more about Dermasilk™ please access www.dermasilkbrands.com.

About Ember Therapeutics, Inc.

Ember Therapeutics, Inc. is a diversified pharmaceutical company commercializing and developing targeted therapies for pain, osteoarthritis, kidney fibrosis and other regenerative medicines. In particular, Ember Therapeutics, Inc. has a commercial stage pain product and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com.

GlobeNewswire
globenewswire.com

Last updated on: 13/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.